A Small HO-soluble Ingredient of Royal Jelly Lower Cholesterol Levels in Liver Cells by Suppressing Squalene Epoxidase

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 Dec 30

PMID 36582688

Authors

Chi Wang

Zhen-Yu Jiang

Jing Wang

Jia-Xin Lou

Yuan-Yuan Nian

Li-Xia Liu

Tong Dang

Xian-Mei Meng

Affiliations

Soon will be listed here.

Abstract

Excessive cholesterol in the liver is harmful for our health and may cause many diseases, such as fatty liver disease. Many studies in human and animal models have reported that royal jelly (RJ) can be used to treat atherosclerosis. However, the real mechanisms behind this action is unclear. In this study, we investigated the efficacy of RJ on gene expression of squalene epoxidase (SE) a major enzyme involved in cholesterol biosynthesis in HepG2 cells. We found that the expression of SE was decreased in response to RJ treatment. We also found that the origin of the RJ affected its strength. To find out the active fraction of RJ in cholesterol suppression, we separated RJ into two parts based on the molecular weights using ultrafiltration membrane. We found that the fraction <10kDa from RJ had comparable effect on SE expression, especially its water-soluble part. Taken together, we think RJ suppresses cholesterol by decreasing SE gene expression in liver. The active fraction of RJ in this action is <10kDa in water-soluble form.

References

VITTEK J . Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Experientia. 1995; 51(9-10):927-35. DOI: 10.1007/BF01921742. View

Brown G, Albers J, Fisher L, Schaefer S, Lin J, Kaplan C . Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323(19):1289-98. DOI: 10.1056/NEJM199011083231901. View

Kamakura M . Royalactin induces queen differentiation in honeybees. Nature. 2011; 473(7348):478-83. DOI: 10.1038/nature10093. View

Pavlov C, Casazza G, Nikolova D, Tsochatzis E, Burroughs A, Ivashkin V . Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015; 1:CD010542. PMC: 7081746. DOI: 10.1002/14651858.CD010542.pub2. View

Ross R, Harker L . Hyperlipidemia and atherosclerosis. Science. 1976; 193(4258):1094-100. DOI: 10.1126/science.822515. View

Yan J, Xie W, Ou W, Zhao H, Wang S, Wang J . Epidemiological survey and risk factor analysis of fatty liver disease of adult residents, Beijing, China. J Gastroenterol Hepatol. 2013; 28(10):1654-9. DOI: 10.1111/jgh.12290. View

Castera L, Friedrich-Rust M, Loomba R . Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(5):1264-1281.e4. PMC: 7505052. DOI: 10.1053/j.gastro.2018.12.036. View

Kamakura M, Moriyama T, Sakaki T . Changes in hepatic gene expression associated with the hypocholesterolaemic activity of royal jelly. J Pharm Pharmacol. 2007; 58(12):1683-9. DOI: 10.1211/jpp.58.12.0017. View

Wong V, Chu W, Wong G, Chan R, Chim A, Ong A . Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2011; 61(3):409-15. DOI: 10.1136/gutjnl-2011-300342. View

10.

Musso G, Gambino R, Cassader M . Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2012; 52(1):175-91. DOI: 10.1016/j.plipres.2012.11.002. View

11.

Vancells Lujan P, Vinas Esmel E, Sacanella Meseguer E . Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients. 2021; 13(5). PMC: 8145877. DOI: 10.3390/nu13051442. View

12.

Li K, Yin R, Huang F, Chen W, Wu J, Cao X . rs7014968 SNP Increases Serum Total Cholesterol Levels and the Risk of Coronary Heart Disease and Ischemic Stroke. Clin Appl Thromb Hemost. 2020; 26:1076029620902844. PMC: 7288804. DOI: 10.1177/1076029620902844. View

13.

Suk K, Kim M, Baik S . Alcoholic liver disease: treatment. World J Gastroenterol. 2014; 20(36):12934-44. PMC: 4177474. DOI: 10.3748/wjg.v20.i36.12934. View

14.

Shi L, Liu Z, Li Y, Gong C, Zhang H, Song L . The prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in Chengdu. Biomed Environ Sci. 2012; 25(4):383-91. DOI: 10.3967/0895-3988.2012.04.002. View

15.

Shen L, Fan J, Shao Y, Zeng M, Wang J, Luo G . Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol. 2003; 9(5):1106-10. PMC: 4611383. DOI: 10.3748/wjg.v9.i5.1106. View

16.

Donato M, Tolosa L, Gomez-Lechon M . Culture and Functional Characterization of Human Hepatoma HepG2 Cells. Methods Mol Biol. 2015; 1250:77-93. DOI: 10.1007/978-1-4939-2074-7_5. View

17.

Lin C, Huang T, Peng Y, Lin Y, Mersmann H, Ding S . A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets. Poult Sci. 2021; 100(3):100869. PMC: 7936157. DOI: 10.1016/j.psj.2020.11.046. View

18.

Kamakura M, Maebuchi M, Ozasa S, Komori M, Ogawa T, Sakaki T . Influence of royal jelly on mouse hepatic gene expression and safety assessment with a DNA microarray. J Nutr Sci Vitaminol (Tokyo). 2005; 51(3):148-55. DOI: 10.3177/jnsv.51.148. View

19.

Heeren J, Scheja L . Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021; 50:101238. PMC: 8324684. DOI: 10.1016/j.molmet.2021.101238. View